Items where authors include "Seymour, M"
Up a levelArticle
Platt, JR, Todd, OM orcid.org/0000-0001-7212-8095, Hall, P et al. (14 more authors) (2023) FOxTROT2: innovative trial design to evaluate the role of neoadjuvant chemotherapy for treating locally advanced colon cancer in older adults or those with frailty. ESMO Open, 8 (1). 100642. ISSN 2059-7029
Lee, RW, Danson, S, Elliot, M et al. (8 more authors) (2022) Importance of clinical research for the UK's 10-year cancer plan. The Lancet Oncology. ISSN 1470-2045
Brown, LC, Graham, J, Fisher, D et al. (15 more authors) (2022) Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer. Clinical Trials, 19 (2). pp. 146-157. ISSN 1740-7745
Pearce, J, Swinson, D, Cairns, D orcid.org/0000-0002-2338-0179 et al. (7 more authors) (2022) Frailty and treatment outcome in advanced gastro-oesophageal cancer: An exploratory analysis of the GO2 trial. Journal of Geriatric Oncology, 13 (3). pp. 265-390. ISSN 1879-4068
Seligmann, JF, Fisher, DJ, Brown, LC et al. (19 more authors) (2021) Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring. Journal of Clinical Oncology, 39 (33). pp. 3705-3715. ISSN 0732-183X
Adams, RA, Fisher, DJ, Graham, J et al. (19 more authors) (2021) Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial. Journal of Clinical Oncology. JCO.21.01436-JCO.21.01436. ISSN 0732-183X
Sirinukunwattana, K, Domingo, E, Richman, SD orcid.org/0000-0003-3993-5041 et al. (21 more authors) (2021) Image-based consensus molecular subtype classification (imCMS) of colorectal cancer using deep learning. Gut, 70. pp. 544-554. ISSN 0017-5749
Malla, SB, Fisher, DJ, Domingo, E et al. (29 more authors) (2020) In-depth clinical and biological exploration of DNA Damage Immune Response (DDIR) as a biomarker for oxaliplatin use in colorectal cancer. Clinical Cancer Research. ISSN 1078-0432
Seligmann, JF, Elliott, F, Richman, S orcid.org/0000-0003-3993-5041 et al. (8 more authors) (2020) Clinical and molecular characteristics and treatment outcomes of advanced right-colon, left-colon and rectal cancers: data from 1180 patients in a phase III trial of panitumumab with an extended biomarker panel. Annals of Oncology, 31 (8). pp. 1021-1029. ISSN 0923-7534
Smyth, EC, Rowley, S, Cafferty, FH et al. (17 more authors) (2019) Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma: A Randomized Phase 2 Clinical Trial. JAMA Oncology, 5 (8). pp. 1181-1187. ISSN 2374-2437
Selby, P, Liu, L, Downing, A orcid.org/0000-0002-0335-7801 et al. (10 more authors) (2019) How can clinical research improve European health outcomes in cancer? Journal of Cancer Policy, 20. ARTN 100182. ISSN 2213-5383
Alexander, S, Bridges, J, Kalsi, T et al. (3 more authors) (2019) Improving outcomes for older people with cancer – A workshop of the UK National Cancer Research Institute. Journal of Geriatric Oncology, 10 (3). pp. 378-381. ISSN 1879-4068
Seymour, M orcid.org/0000-0002-2441-9629 (2019) Choosing the right strategy based on individualized treatment effect predictions: combination versus sequential chemotherapy in patients with metastatic colorectal cancer. Acta Oncologica, 58 (3). pp. 326-333. ISSN 0284-186X
Adams, R, Brown, E, Brown, L et al. (14 more authors) (2018) Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial. Lancet Gastroenterology and Hepatology, 3 (3). pp. 162-171. ISSN 2468-1253
Hutchins, GGA orcid.org/0000-0002-1707-4415, Treanor, D orcid.org/0000-0002-4579-484X, Wright, A et al. (9 more authors) (2018) Intra-tumoural stromal morphometry predicts disease recurrence but not response to 5-fluorouracil – results from the QUASAR trial of colorectal cancer. Histopathology, 72 (3). pp. 391-404. ISSN 0309-0167
Davidson, M, Chau, I, Cunningham, D et al. (5 more authors) (2017) Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer. World Journal of Gastrointestinal Oncology, 9 (8). pp. 333-340. ISSN 1948-5204
Seligmann, JF, Fisher, D, Smith, CG et al. (9 more authors) (2017) Investigating the poor outcomes of BRAF - mutant advanced colorectal cancer: Analysis from 2530 patients in randomised clinical trials. Annals of Oncology, 28 (3). pp. 562-568. ISSN 0923-7534
Downing, A orcid.org/0000-0002-0335-7801, Morris, EJA orcid.org/0000-0002-1075-6544, Corrigan, N et al. (13 more authors) (2017) High hospital research participation and improved colorectal cancer survival outcomes: a population-based study. Gut, 66 (1). pp. 89-96. ISSN 0017-5749
Smyth, E, Rowley, S, Allum, W et al. (17 more authors) (2016) A randomised phase II study of perioperative epirubicin, cisplatin and capecitabine (ECX) ± lapatinib for operable, HER-2 positive gastric, oesophagogastric junctional (OGJ) or lower oesophageal adenocarcinoma: Results from the UK MRC ST03 lapatinib feasibility study (ISRCTN 46020948). Annals of Oncology, 27 (suppl_6). LBA26. ISSN 0923-7534
Richman, SD orcid.org/0000-0003-3993-5041, Southward, K, Chambers, P orcid.org/0000-0002-0926-717X et al. (16 more authors) (2016) HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: Analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. Journal of Pathology, 238 (4). pp. 562-570. ISSN 0022-3417
Smith, CG, Fisher, D, Harris, R et al. (15 more authors) (2015) Analyses of 7,635 Patients with Colorectal Cancer Using Independent Training and Validation Cohorts Show That rs9929218 in CDH1 Is a Prognostic Marker of Survival. Clinical Cancer Research, 21 (15). pp. 3453-3461. ISSN 1078-0432
Casali, PG, Bruzzi, P, Bogaerts, J et al. (61 more authors) (2015) Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper. Annals of Oncology, 26 (2). pp. 300-306. ISSN 0923-7534
Bogaerts, J, Sydes, MR, Keat, N et al. (43 more authors) (2014) Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. European journal of cancer. ISSN 0014-2964
Papamichael, D, Audisio, RA, Glimelius, B et al. (14 more authors) (2014) Treatment of colorectal cancer in older patients. International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Annals of Oncology. ISSN 1569-8041
Rosmarin, D, Palles, C, Church, D et al. (41 more authors) (2014) Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. Journal of Clinical Oncology, 32 (10). 1031 - 1039. ISSN 0732-183X
Negrouk, A, Lacombe, D, Trimble, EL et al. (1 more author) (2014) Clinical research for rare cancers: is it a reality in the global regulatory landscape? The international rare cancer initiative. Expert opinion on orphan drugs, 2 (5). 433 - 440. ISSN 2167-8707
Middleton, G, Brown, S, Lowe, C et al. (17 more authors) (2013) A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO). European Journal of Cancer, 49 (16). 3507 - 3516. ISSN 0959-8049
Smith, CG, West, H, Harris, R et al. (12 more authors) (2013) Role of the oxidative DNA damage repair gene OGG1 in colorectal tumorigenesis. Journal of the National Cancer Institute, 105 (16). 1249 - 1253. ISSN 0027-8874
Book Section
Seligmann, J, Messenger, M orcid.org/0000-0002-4975-0158, Seymour, M et al. (1 more author) (2017) Clinical Trials in Precision Oncology. In: Copson, ER, Hall, P, Board, RE, Cook, G and Selby, P, (eds.) Problem Solving Through Precision Oncology: A Case Study Based Reference and Learning Resource. Clinical Publishing , Abingdon, Oxon, UK . ISBN 978-1-84692-111-7
Conference or Workshop Item
Adams, R, Fisher, D, Graham, J et al. (13 more authors) (2021) Oral maintenance capecitabine versus active monitoring for patients with metastatic colorectal cancer (mCRC) who are stable or responding after 16 weeks of first-line treatment: Results from the randomized FOCUS4-N trial. In: 2021 ASCO Annual Meeting I, 04-08 Jun 2021, Online.
Yin, J, Cohen, R, Jin, Z et al. (16 more authors) (2020) Prognostic and predictive impact of primary tumor sidedness in first-line trials for advanced colorectal cancer: An analysis of 7,828 patients in the ARCAD database. In: 2020 Gastrointestinal Cancers Symposium, 23-25 Jan 2020, San Francisco, California.
Hall, P, Swinson, D, Lord, S et al. (23 more authors) (2019) Optimizing Chemotherapy for Frail and Elderly Patients with Advanced Gastroesophageal Cancer (aGOAC): the GO2 Phase III Trial. In: 2019 NCRI Cancer Conference of National Cancer Research Institute, 03-05 Nov 2019, Glasgow, Scotland, UK.
Proceedings Paper
Murakami, K, West, N orcid.org/0000-0002-0346-6709, Richman, SD orcid.org/0000-0003-3993-5041 et al. (6 more authors) (2019) Central Pathological Review of the International Phase III FOxTROT Trial: Comparison with the Local Pathological Evaluation. In: Journal of Pathology. Leeds Pathology 2019. 12th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland, 02-04 Jul 2019, Leeds. Wiley , S39-S39.
Murakami, K, West, NP orcid.org/0000-0002-0346-6709, Richman, SD orcid.org/0000-0003-3993-5041 et al. (6 more authors) (2019) The Effect of Pre-Operative FOLFOX Chemotherapy in Advanced Colon Cancer on Histopathological Features: Analysis of the International Phase III FOxTROT Trial. In: Journal of Pathology. Leeds Pathology 2019. 12th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland, 02-04 Jul 2019, Leeds. Wiley , S38-S38.
West, NP orcid.org/0000-0002-0346-6709, Richman, SD orcid.org/0000-0003-3993-5041, Magill, L et al. (5 more authors) (2019) FOxTROT: An International Randomised Controlled Trial Evaluating Neoadjuvant Chemotherapy for Colon Cancer in 1,052 Patients. In: Journal of Pathology. Leeds Pathology 2019. 12th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland, 02-04 Jul 2019, Leeds. Wiley , S20-S20.
Murakami, K, West, NP orcid.org/0000-0002-0346-6709, Westwood, AC et al. (10 more authors) (2019) The Relationship Between DNA Mismatch Repair and Response to FOLFOX-based Pre-operative Chemotherapy in the International Phase III FOxTROT Trial. In: Journal of Pathology. Leeds Pathology 2019. 12th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland, 02-04 Jul 2019, Leeds. Wiley , S17-S17.
Murakami, K, West, NP orcid.org/0000-0002-0346-6709, Ide, R et al. (7 more authors) (2019) The Relationship Between Tumour Immune Profile and Response to FOLFOX-Based Pre-Operative Chemotherapy in the International Phase III FOxTROT Trial. In: Journal of Pathology. Leeds Pathology 2019. 12th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland, 02-04 Jul 2019, Leeds. Wiley-Blackwell , S37-S37.
Westwood, AC, Hemmings, GJ, Bottomley, D et al. (7 more authors) (2018) Comparison of Mismatch Repair Protein Expression Between Biopsies and Resections in Advanced Colon Cancer from the Phase II Group of the Fluoropyrimidine Oxaliplatin and Targeted Receptor Pre-Operative Therapy (FOxTROT) Trial. In: Journal of Pathology. Maastricht Pathology 2018. 11th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland, 19-22 Jun 2018, Maastricht. Wiley , S26-S26.
Westwood, AC, Bottomley, D, Hemmings, GJ et al. (11 more authors) (2018) Comparison of Mutational Status in the EGFR Pathway Across Four Different Platforms in the Fluoropyrimidine Oxaliplatin and Targeted Receptor Pre-Operative Therapy (FOxTROT) Trial. In: Journal of Pathology. Maastricht Pathology 2018. 11th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland, 19-22 Jun 2018, Maastricht. Wiley , S15-S15.
Seligmann, J, Wood, H orcid.org/0000-0003-3009-5904, Richman, S orcid.org/0000-0003-3993-5041 et al. (6 more authors) (2017) 545P Epidermal growth factor receptor (EGFR) copy number (CN) as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC). In: Annals of Oncology. 42nd ESMO Congress (ESMO 2017), 08-12 Sep 2017, Madrid, Spain. Oxford University Press , p. 185.
Turnbull, S, West, E, Scott, K orcid.org/0000-0002-5790-9579 et al. (5 more authors) (2017) Revealing potential immune responses (IRs) in patients with advanced colorectal cancer (aCRC) on first line chemotherapy: A prospective study of neutrophil to lymphocyte ratio, immune function and outcome. In: Annals of Oncology. ESMO 2017 Congress, 08-12 Sep 2017, Madrid, Spain. Oxford University Press .
Adams, RA, Brown, E, Brown, L et al. (13 more authors) (2016) FOCUS4-D: Results from a randomised, placebo controlled trial (RCT) of AZD8931 (an inhibitor of signalling by HER1, 2, and 3) in patients (pts) with advanced or metastatic colorectal cancer (aCRC) in tumours that are wildtype (wt) for BRAF, PIK3CA, KRAS & NRAS. In: Annals of Oncology. 41st ESMO Congress (ESMO 2016), 07-11 Oct 2016, Copenhagen. Oxford University Publishing .